Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease
Open Label Prospective Study of High Dose Ropinirole for Motor Fluctuations and Dyskinesias in Advanced Parkinson's Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Deborah Judd, RN, CCRC
- Phone Number: 303-762-6667
- Email: judd@megapathdsl.net
Study Locations
-
-
Colorado
-
Englewood, Colorado, United States, 80113
- Recruiting
- Colorado Neurology, P.C.
-
Contact:
- Deborah Judd, RN, CCRC
- Phone Number: 303-762-6667
- Email: judd@megapathdsl.net
-
Principal Investigator:
- Pinky Agarwal, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must give written informed consent prior to any specific study procedures.
- Males or females; females of childbearing age who are not currently pregnant must agree to use a medically accepted method of contraception throughout the study.
- Age greater than or equal to 25 years.
- Patients must be on a maximum dose of dopamine agonist drug (pergolide 4mg/day, pramipexole 4.5 mg/day or ropinirole 24mg/day).
- Stable dose of all medications for 4 weeks.
Exclusion Criteria:
- Current hallucinations.
- History of disabling hallucinations or hallucinations in past requiring treatment.
- Troublesome edema (swelling).
- Unstable depression.
- Female who is pregnant or lactating.
- Use of an investigational drug with in the last 30 days.
- Other inclusion or exclusion criteria to be evaluated by the physician.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Pinky Agarwal, MD, Colorado Neurology, P.C.
Study record dates
Study Major Dates
Study Start
Study Start
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Parkinson Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Dopamine Agonists
- Dopamine Agents
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Ropinirole
Other Study ID Numbers
Other Study ID Numbers
- 103911
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.